Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers

Hepato-Gastroenterology

Volumn 48, Issue 40, 2001, Pages 1124-1128

  Ueno, T ^a   Ide, T ^a   Hashimoto, O ^a   Uchimura, Y ^a   Torimura, T ^a   Kumashiro, R ^a   Inuzuka, S ^a   Sata, M ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Fibrosis marker; Hyaluronan; Inteferon

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN TYPE 4; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; POSTOPERATIVE PERIOD;

EID: 0034886181     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon
2. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial
3. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial
4. Transforming growth factors β and α in chronic liver disease: Effects of interferon alfa therapy
5. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α therapy
6. Long-term follow-up of patients with chronic hepatitis C after interferon-alpha treatment
7. Long-term biological and virological response to natural interferon-α in patients with chronic hepatitis C
8. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C
9. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients
10. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment
11. 10-Year follow-up after interferon-α therapy for chronic hepatitis C
12. Significance of serum type-IV collagen levels in various liver diseases
13. Serum hyaluronate reflects hepatic sinusoidal capillarization
14. Lymphoblastoid α-interferon for chronic hepatitis C: A randomized controlled study
15. Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C
16. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon
17. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha
18. Pro-collagen-III peptide and chronic viral C hepatitis
19. Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon
20. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis C
21. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C
22. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
23. Assay of serum hyaluronic acid in clinical application
24. Radioimmunoassay for type III procollagen peptide and its application to human liver disease
25. One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies
26. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
27. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
28. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
29. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C